Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syngen Biotech CoROCO:8279 +1.03%89 Days Payable is 30.49 as of Dec. 2025, which is 11% above its 10-year median of 27.41. GuruFocus rates ROCO:8279 with a GF Score™ of 89/100 and a GF Value™ of NT$158.16 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Syngen Biotech Co ranks worse than 81.34% on this metric.
The historical rank and industry rank for Syngen Biotech Co's Days Payable or its related term are showing as below:
ROCO:8279'
s Days Payable Range Over the Past 10 Years
Min: 21.81 Med: 27.41 Max: 45.49
Current: 28.84
During the past 13 years, Syngen Biotech Co's highest Days Payable was 45.49. The lowest was 21.81. And the median was 27.41.
ROCO:8279's Days Payable is ranked worse than 81.34% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs ROCO:8279: 28.84
Syngen Biotech Co's Days Payable
increased
from Dec. 2024 (27.39) to Dec. 2025 (30.49).
It may suggest that Syngen Biotech Codelayed paying its suppliers.
Syngen Biotech Co Days Payable Related Terms
Syngen Biotech Co Days Payable Historical Data
* Premium members only.
The historical data trend for Syngen Biotech Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8279 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Syngen Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngen Biotech Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syngen Biotech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Syngen Biotech Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Syngen Biotech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngen Biotech Co (ROCO:8279) has a Days Payable of 30.49 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Syngen Biotech Co and its competitors. This is 11% above median its historical median of 27.41. Over the past decade, Syngen Biotech Co's Days Payable has ranged from 21.81 to 45.49. According to the industry distribution chart, Syngen Biotech Co ranks #571 out of 702 companies in the Biotechnology industry, placing it in the top 81.3%.
Is Syngen Biotech Co's Days Payable too high?
Syngen Biotech Co's current Days Payable of 30.49 is 11% above median its 10-year median of 27.41. Over the past 10 years, this metric has ranged from a low of 21.81 to a high of 45.49. The Biotechnology industry median Days Payable is 113.10. Syngen Biotech Co's value of 30.49 is 73% below this industry median. Based on the distribution chart, Syngen Biotech Co ranks #571 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syngen Biotech Co has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngen Biotech Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syngen Biotech Co ranks #571 out of 702 companies for Days Payable. This places Syngen Biotech Co in the lower half of its industry. The industry median Days Payable is 113.10. Syngen Biotech Co's value of 30.49 is 73% below this benchmark. Historically, Syngen Biotech Co's own Days Payable has ranged from 21.81 to 45.49 over the past decade. While the company's 10-year median is 27.41 vs. the industry median of 113.10, Syngen Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syngen Biotech Co's current Days Payable of 30.49 is 73% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Syngen Biotech Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syngen Biotech Co's current Days Payable is 30.49, which is 11% above median its own 10-year median of 27.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Syngen Biotech Co (ROCO:8279) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$158.16, compared to a current price of NT$88.50 — trading 44% below its estimated fair value. The current Days Payable is 30.49, which is 11% above median its 10-year median of 27.41 and 73% below the Biotechnology industry median of 113.10. Syngen Biotech Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Syngen Biotech Co (ROCO:8279), the current Days Payable is 30.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngen Biotech Co (ROCO:8279) Overvalued in 2026?
Based on GuruFocus' analysis, Syngen Biotech Co stock appears to be undervalued.
The current stock price of NT$88.50 is trading 44% below its estimated GF Value™ of NT$158.16.
GuruFocus considers Syngen Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:8279:
Days Payable: 30.49 (11% above median its 10-year median of 27.41)
GF Value™: NT$158.16 vs. price of NT$88.50 (44% below fair value)
Industry Position: 73% below the Biotechnology median (#571 of 702)
No single metric tells the full story. See the ROCO:8279 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngen Biotech Co Ltd is a biotechnology company. It is engaged in the manufacturing, sales, and trading of microbial pharmaceutical raw materials. It also provides the design and development of health food and biochemical nutrition. The company's products include pharmaceutical ingredients, nutritional ingredients, biology fermentation products, biology agriculture and aquaculture products.
89GF Score
Get the complete analysis for ROCO:8279
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8279 has been successfully added to your 
